[go: up one dir, main page]

AU2193797A - Delivery of therapeutic agents to the prostate - Google Patents

Delivery of therapeutic agents to the prostate

Info

Publication number
AU2193797A
AU2193797A AU21937/97A AU2193797A AU2193797A AU 2193797 A AU2193797 A AU 2193797A AU 21937/97 A AU21937/97 A AU 21937/97A AU 2193797 A AU2193797 A AU 2193797A AU 2193797 A AU2193797 A AU 2193797A
Authority
AU
Australia
Prior art keywords
prostate
delivery
therapeutic agents
therapeutic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21937/97A
Inventor
David T. Hung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2193797A publication Critical patent/AU2193797A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
AU21937/97A 1996-03-01 1997-02-28 Delivery of therapeutic agents to the prostate Abandoned AU2193797A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US1267296P 1996-03-01 1996-03-01
US60012672 1996-03-01
US1281796P 1996-03-05 1996-03-05
US60012817 1996-03-05
US2153996P 1996-07-11 1996-07-11
US60021539 1996-07-11
US80718197A 1997-02-27 1997-02-27
US08807181 1997-02-27
PCT/US1997/003228 WO1997031611A2 (en) 1996-03-01 1997-02-28 Treatment of begnin prostatic hyperplasia

Publications (1)

Publication Number Publication Date
AU2193797A true AU2193797A (en) 1997-09-16

Family

ID=27486210

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21937/97A Abandoned AU2193797A (en) 1996-03-01 1997-02-28 Delivery of therapeutic agents to the prostate

Country Status (3)

Country Link
EP (1) EP0886524A2 (en)
AU (1) AU2193797A (en)
WO (1) WO1997031611A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3454799A (en) * 1998-03-30 1999-10-18 Baylor College Of Medicine Regulated apoptosis using chemically induced dimerization of apoptosis factors
ES2269138T3 (en) 1999-04-30 2007-04-01 Cellgate, Inc. POLYAMINS AND ITS USE IN THERAPY.
AU4678000A (en) * 1999-04-30 2000-11-17 Slil Biomedical Corporation Quinones for treatment of diseases
BR0010700A (en) 1999-04-30 2002-02-13 Slil Biomedical Corp Analog conjugates of polyamine and quinone conjugates as therapies for cancers and prostate diseases
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
AU1070901A (en) * 1999-09-23 2001-04-24 Genvec, Inc. Method of treating cells of the prostate prophylactically or therapeutically
US6939896B2 (en) * 1999-12-21 2005-09-06 Astrazeneca Ab Cd45 inhibitors
EP1337504A4 (en) 2000-11-08 2005-10-05 Cellgate Inc NOVEL AMINO ACID CONJUGATES AND POLYAMINE ANALOGUES USEFUL AS ANTICANCING AGENTS
JP2005511734A (en) 2001-12-07 2005-04-28 スリル バイオメディカル コーポレイション Cycloalkyl-substituted polyamines for cancer treatment and methods for their synthesis
US7837670B2 (en) 2005-03-22 2010-11-23 Boston Scientific Scimed, Inc. Methods and devices for delivering therapeutic agents into the prostate gland

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007897A (en) * 1989-05-30 1991-04-16 Kalb Irvin M Drug delivery catheter
WO1994006910A1 (en) * 1992-09-18 1994-03-31 Canji, Inc. Gene therapy by retroviral vector with tumor suppressive gene
EP0639573A1 (en) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzocondensed five membered heterocycles, process of their preparation, their use as drug, as diagnostic means and pharmaceuticals containing it
WO1995023141A1 (en) * 1994-02-23 1995-08-31 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
DE4421536A1 (en) * 1994-06-20 1995-12-21 Hoechst Ag Phenyl-substituted alkenylcarboxylic acid guanidines bearing perfluoroalkyl groups, processes for their preparation, their use as medicaments or diagnostic agents, and medicaments containing them

Also Published As

Publication number Publication date
WO1997031611A2 (en) 1997-09-04
WO1997031611A3 (en) 1997-11-13
EP0886524A2 (en) 1998-12-30

Similar Documents

Publication Publication Date Title
AU1403199A (en) Local delivery of therapeutic agents
GB9701206D0 (en) Serine derivatives and their use as therapeutic agents
AUPO203996A0 (en) Therapeutic uses
AU6513298A (en) Therapeutic compositions
AU6721598A (en) Dioxino derivatives and their use as therapeutic agents
GB9600235D0 (en) Therapeutic agents
GB9603755D0 (en) Therapeutic agents
GB9613969D0 (en) Therapeutic agents
AU2193797A (en) Delivery of therapeutic agents to the prostate
GB9615449D0 (en) Therapeutic agents
GB9609374D0 (en) Therapeutic agents
GB9605065D0 (en) Therapeutic agents
AU1171099A (en) Therapeutic agents
AU7920198A (en) Intratumoral administration of triphenylethylenes for the treatment of cancer
GB9610979D0 (en) Therapeutic agents
AU8760298A (en) Coup-tfi directed therapies in the treatment of disease
AU1801297A (en) Spiro-ketal derivatives and their use as therapeutic agents
GB9604036D0 (en) Therapeutic agents
GB9615658D0 (en) Therapeutic agents
AUPO314896A0 (en) Therapeutic agent
GB9610978D0 (en) Therapeutic agents
GB9601786D0 (en) Therapeutic agents
AUPP105997A0 (en) Therapeutic agents
GB9607230D0 (en) Therapeutic targeting
AUPM656394A0 (en) Therapeutic agents